10Aug 2021
Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

Current psoriasis therapies have little‐to‐no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE‐4) inhibitor, is approved for moderate‐to‐severe psoriasis and considered a safe treatment option, that does not require laboratory monitoring. Nonetheless, lower efficacy compared with novel similar priced biologics, have led to modest use of apremilast in some countries...

  • #dermatology

Like

Save

Share